NCT00222469 - Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

bevacizumab

10mg/kg IV on Day 1 Q 2 weeks

DRUG

gemcitabine

1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.

DRUG

oxaliplatin

100mg/m2 on Day 2 and Q 2 weeks.

Trial Locations (2)

University of Oklahoma, Oklahoma City

MD Anderson Cancer Center, Houston